Overview
Overview
From February to April 2024, NICE carried out a public consultation on proposed interim methods and processes for including NICE technology appraisals in NICE guidelines.
The comments we received in the consultation were extensive and wide ranging, with different stakeholder groups sharing often-polarised views on key aspects of our proposals.
We set out a way forward which will see NICE proceeding with incorporation of technology appraisals in guidelines - in line with NICE's commitment under the 2024 voluntary scheme for branded medicines pricing, access and growth – a proposal that was generally well received by all stakeholder groups and which stands to improve user experience and increase adoption of our guidance, leading to better patient outcomes. But we will not progress the approach we proposed for integration at this stage. Instead, we will continue to review and update our approach to incorporation as required focusing initially on areas where incorporation is not likely to meet user needs.
The approach set out has been developed to support NICE's strategic ambition to produce high quality guidance that is relevant, timely, useable and impactful, and to provide clarity on the interim methods and processes that can be used to bring NICE technology appraisal guidance into NICE guidelines.